We are live on ! Find out more
LXEO icon

Lexeo Therapeutics
LXEO

90 hedge funds and large institutions have $194M invested in Lexeo Therapeutics in 2024 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 30 increasing their positions, 11 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

263% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 8

173% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 11

30% more funds holding

Funds holding: 69 → 90 (+21)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.68% less ownership

Funds ownership: 89.94% → 89.26% (-0.68%)

28% less capital invested

Capital invested by funds: $269M → $194M (-$74.6M)

Holders
90
Holders Change
+21
Holders Change %
+30.43%
% of All Funds
1.19%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
29
Increased
30
Reduced
11
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$4.54M
2
ACM
Altium Capital Management
New York
+$3.19M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$2.99M
4
VPC
Vestal Point Capital
New York
+$2.76M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$2M

Top Sellers

Rank Fund Capital Flow
1
OFM
Omega Fund Management
Massachusetts
-$9.23M
2
B
Braidwell
Connecticut
-$6.59M
3
EAM
Eventide Asset Management
Massachusetts
-$4.89M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$3.06M
5
DCP
D1 Capital Partners
New York
-$2.38M
Name Holding Trade Value Shares
Change 		Change in
Stake
BFM
26
Boothbay Fund Management
New York
$973K +$318K +40,323 +38%
Millennium Management
27
Millennium Management
New York
$934K +$826K +104,837 +282%
PA
28
Perceptive Advisors
New York
$920K – – –
PFM
29
Privium Fund Management
Netherlands
$909K +$1.09M +138,115 New
OM
30
Opaleye Management
Massachusetts
$855K +$1.02M +130,000 New
Goldman Sachs
31
Goldman Sachs
New York
$598K +$111K +14,150 +18%
Wellington Management Group
32
Wellington Management Group
Massachusetts
$507K +$198K +25,089 +48%
Morgan Stanley
33
Morgan Stanley
New York
$492K -$1.32M -167,000 -69%
BCM
34
Bridgeway Capital Management
Texas
$428K +$512K +65,000 New
Charles Schwab
35
Charles Schwab
California
$420K – – –
Walleye Capital
36
Walleye Capital
New York
$407K +$488K +61,930 New
Barclays
37
Barclays
United Kingdom
$363K +$39K +4,951 +10%
SCM
38
Superstring Capital Management
New York
$346K +$414K +52,616 New
UBS Group
39
UBS Group
Switzerland
$336K +$315K +39,942 +359%
Bank of New York Mellon
40
Bank of New York Mellon
New York
$333K +$21.1K +2,677 +6%
N
41
Nuveen
North Carolina
$237K – – –
BNP Paribas Financial Markets
42
BNP Paribas Financial Markets
France
$227K +$228K +28,986 +523%
Bank of America
43
Bank of America
North Carolina
$200K -$66.2K -8,409 -22%
AC
44
Aristides Capital
Kentucky
$193K +$231K +29,285 New
RhumbLine Advisers
45
RhumbLine Advisers
Massachusetts
$166K +$32.5K +4,127 +20%
Citigroup
46
Citigroup
New York
$164K +$14.3K +1,819 +8%
JF
47
Jump Financial
Illinois
$134K +$161K +20,400 New
CC
48
Caxton Corporation
New Jersey
$117K – – –
Marshall Wace
49
Marshall Wace
United Kingdom
$117K +$140K +17,794 New
PFCS
50
Pale Fire Capital SE
Czech Republic
$106K +$127K +16,100 New
1
2
3 4

LXEO Hedge Fund Activity: Q4 2024 in Review

90 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Lexeo Therapeutics (LXEO) for Q4 2024, worth a combined $194M — down 28% from $269M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new LXEO positions and 8 closed out — a net gain of 21 holders — while 30 added to existing stakes and 11 trimmed.

The largest buyer was Janus Henderson Group, adding an estimated $4.54M. The largest seller was Omega Fund Management, cutting an estimated $9.23M.

  • 90 institutional investors held Lexeo Therapeutics (LXEO) as of Q4 2024, up from 69 in Q3 2024.
  • Funds reported $194M of Lexeo Therapeutics stock for Q4 2024, down 28% quarter-over-quarter.
  • 29 funds opened new Lexeo Therapeutics positions in Q4 2024 and 8 closed out, a net change of +21 holders.
  • The largest Lexeo Therapeutics buyer in Q4 2024 was Janus Henderson Group, an estimated $4.54M added.
  • The largest Lexeo Therapeutics seller in Q4 2024 was Omega Fund Management, an estimated $9.23M sold.

Based on aggregated 13F filings for Q4 2024.